



**Vaccines and Global Health: The Week in Review**  
**01 March 2025 :: Issue 788**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

## ***Milestones, Perspectives***

.....  
.....

### **Polio – PHEIC**

#### **Polio this week – 26 February 2025**

##### ***Headlines***

:: Kingdom of Saudi Arabia confirms US\$500 million commitment to global polio eradication effort, in a signing event during the fourth Riyadh International Humanitarian Forum. [More](#).

:: Gaza outbreak response underway. Daily situation reports from the response are available at the bottom of this [page](#).

:: Afghanistan Technical Advisory Group urges strong action to eradicate polio in the [country](#).

##### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Pakistan: one WPV1 case and 13 WPV1-positive environmental samples
- Chad: six cVDPV2 cases and one cVDPV2-positive environmental sample
- Côte d'Ivoire: one cVDPV2-positive environmental sample
- Djibouti: two cVDPV2-positive environmental samples
- Ethiopia: five cVDPV2 cases
- Germany: four cVDPV2-positive environmental samples
- Poland: one cVDPV2-positive environmental sample
- United Kingdom: one cVDPV2-positive environmental sample
- Yemen: two cVDPV2 cases

.....

#### **Humanitarian access improves quality of polio vaccination campaign in the Gaza Strip**

*Polio campaign in Gaza Strip reaches around 603 000 children with better access*

28 February 2025 *Joint News Release*

**A five-day mass polio vaccination campaign in the Gaza Strip concluded on Wednesday, reaching nearly 603 000 children under 10 years of age with novel oral polio vaccine type 2 (nOPV2)** following comprehensive, simultaneous access to all five governorates during the ongoing ceasefire. The campaign was conducted as part of emergency efforts to end an ongoing poliovirus outbreak and prevent further spread in the Gaza Strip.

**During this round, an additional 40 000 children were vaccinated as compared to the previous two rounds conducted in September and October 2024**, after poliovirus was detected in the Gaza Strip. The ceasefire enabled health workers to reach more children who had missed vaccinations due to displacement during the phased approach, living in areas that previously required special coordination for access, or being unreachable during the October 2024 round due to insecurity in North Gaza, including Jabalia, Beit Lahiya, and Beit Hanoun.

**Strong community engagement and awareness of vaccination benefits had maintained high immunization rates in the Gaza Strip**, where 89% of children received the third dose of oral polio vaccine in 2023, before the conflict. **This round drew upon 1660 vaccination teams**, 1242 of which were mobile, and deployed 1242 social mobilizers. Despite bad weather conditions, families welcomed the initiative and brought their children to points where they could receive the polio vaccine.

**The campaign was conducted by the Palestinian Ministry of Health and implemented with support from the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), the United Nations Relief and Works Agency for Palestine Refugees (UNRWA), and other partners...**

WHO, UNICEF and partners continue to call for a lasting ceasefire that leads to long-term health and peace.

.....  
.....

## **mPox – PHEIC**

### **Third meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024 – Temporary recommendations**

27 February 2025 Statement

The Director-General of the World Health Organization (WHO), following the third meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the upsurge of mpox 2024, held on 25 February 2025, from 12:00 to 17:00 CET, **concurs with its advice that the event continues to meet the criteria of a public health emergency of international concern and, considering the advice of the Committee, he is hereby issuing a revised set of temporary recommendations...**

#### ***Temporary recommendations***

These temporary recommendations are issued to States Parties experiencing the transmission of monkeypox virus (MPXV), including, but not limited to, those where there is sustained community transmission, and where there are clusters of cases or sporadic travel-related cases of MPXV clade Ib.

They are intended to be implemented by those States Parties in addition to the current standing recommendations for mpox, which will be extended until 20 August 2025.

In the context of the global efforts to prevent and control the spread of mpox disease outlined in the WHO Strategic framework for enhancing prevention and control of mpox- 2024-2027, the aforementioned standing recommendations apply to all States Parties.

All current WHO interim technical guidance can be accessed on this page of the WHO website. WHO evidence-based guidance has been and will continue to be updated in line with the evolving situation, updated scientific evidence, and WHO risk assessment to support States Parties in the implementation of the WHO Strategic Framework for enhancing mpox prevention and control.

Pursuant to Article 3 Principle of the International Health Regulations (2005) (IHR), the implementation of these temporary recommendations, as well as of the standing recommendations for mpox, by States Parties shall be with full respect for the dignity, human rights and fundamental freedoms of persons, in line with the principles set out in Article 3 of the IHR.

*[Excerpt from Temporary Recommendations]*

#### ***...Vaccination***

- Prepare for and implement the integrated targeted use of vaccine for “Phase 1-Stop the outbreak” (as defined in the WHO Mpox global strategic preparedness and response plan (2024) and its upcoming iteration) through identification of the lowest administrative level reporting cases (hotspots) to interrupt sustained community transmission. (EXTENDED, with re-phrasing)
- Develop and implement plans for vaccination in the context of an integrated response at the lowest administrative level reporting cases for people at high risk of exposure (e.g., contacts of cases of all

ages, including sexual contacts, health and care workers, key populations, and other groups at risk in endemic and non-endemic areas). This entails a targeted integrated response, including active surveillance and contact tracing; agile adaptation of immunization strategies and plans to the local context including the availability of vaccines and supplies; proactive community engagement to generate and sustain demand for and trust in vaccination; close monitoring of mpox vaccination activities and coverage, and the collection of data during vaccination activities according to implementable research protocols. (EXTENDED, with re-phrasing)

.....  
.....

## Featured Journal Content

### BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 01 Mar 2025)

#### Research

#### **[How have PHEIC determinations changed since the COVID-19 pandemic? A document analysis of 101 WHO International Health Regulations Emergency Committees' statements](#)**

Authors: Kevin Hemmat, Michelle Amri and Daniel Eisenkraft Klein

Citation: BMC Public Health 2025 25:818

Published on: 28 February 2025

#### Abstract

##### Background

The World Health Organization (WHO) is chiefly responsible for declaring a Public Health Emergency of International Concern (PHEIC). The WHO makes the assessment on whether to declare a formal PHEIC if the event fulfils three criteria: (i) it is an extraordinary event, (ii) is a public health risk to other States through the international spread of disease, and (iii) potentially requires a coordinated international response. There have been seven PHEIC declarations, including for the 2009 H1N1 flu pandemic, Ebola and Polio outbreaks, the COVID-19 pandemic, and most recently, the mpox outbreak. While the WHO's approach to PHEIC declarations prior to COVID-19 has been previously analyzed, there has been limited scholarly attention to how the approach has shifted since the pandemic. Given that COVID-19 constitutes the most severe pandemic in a century, this study empirically assesses how the PHEIC declaration process has been impacted by, and what has changed during and after, the COVID-19 pandemic.

##### Method

A document analysis of 101 WHO International Health Regulations Emergency Committees' (EC) statements was undertaken with inductive thematic analysis. The thematic analysis focused on identifying common patterns in the EC statements to ascertain changes to PHEICs since COVID-19.

##### Results

Three primary themes emerged from our analysis: (i) this work affirms previous findings that the rationale for a PHEIC declaration and the criteria used to declare PHEICs have been applied inconsistently; (ii) since the COVID-19 pandemic, there has been a greater focus in explaining and justifying the use of the three criteria for PHEIC declarations and terminations; and (iii) since the COVID-19 pandemic, there has been increased detail, discussion, and structure in IHR EC statements.

##### Discussion

This analysis suggests that changes to the PHEIC process are needed and we present two primary recommendations: first, to create a new standardized interpretation of PHEIC criteria; and second, for the WHO EC to reaffirm its commitment to clear and transparent communications.

##### Conclusion

Given changes to the PHEIC declaration process following the COVID-19 pandemic, it is evident that reforms are necessary to ensure a more consistent, transparent, and effective global health response

moving forward. Our recommendations, if adopted, could significantly enhance the WHO's ability to respond to future global health crises, ensuring more consistent and transparent decision-making in PHEIC declarations, and ultimately strengthening international preparedness and cooperation.

.....  
.....

## **U.S. Foreign Aid – Immunization**

### **Impact of the "Reevaluating and Realigning United States Foreign Aid" Executive Order on Routine Immunization Programs**

CSIS Event – *Video On Demand*

February 19, 2025

**The January 20 Executive Order pausing United States foreign development assistance for a 90-day review effectively stopped work on a wide variety of U.S.-supported global health security programs, including routine immunizations.** While the Secretary of State's January 29 emergency waiver specified that "implementers of existing life-saving humanitarian assistance programs should continue or resume work if they have stopped," the extent to which support for vaccinations to prevent infectious disease is covered is unclear.

A February 4 USAID information memo outlining Bureau for Global Health programming that will continue under **the waiver singles out "essential immunizations to prevent imminent mortality" for newborns and children, but work related to transporting vaccines, analyzing data related to immunization coverage, supporting health workers to administer vaccines, and reaching populations in remote, hard-to-reach districts is not described.** Yet with measles outbreaks being reported in the U.S. and abroad, and with coverage of the 3rd dose of diphtheria-tetanus-pertussis vaccine still lower than before the Covid-19 pandemic, ensuring countries have the support needed to deliver vaccines to populations at risk of vaccine preventable disease remains a high priority to both stop outbreaks overseas and protect global health security.

**[The broadcast] featured a broadcast conversation with Nidhi Bouri, former Deputy Assistant Administrator for Global Health, USAID; Grace Chee, former Director of the MOMENTUM Routine Immunization Transformation and Equity (MRITE); and William Moss, Professor and Executive Director of the International Vaccine Access Center at the Johns Hopkins University Bloomberg School of Public Health,** regarding the current state of routine immunizations programs and the impacts of the recent executive orders on U.S. foreign assistance and global health. Katherine E. Bliss, CSIS Senior Fellow and Director, Immunizations and Health Systems Resilience with the Global Health Policy Center, moderated.

*This event is made possible through the generous support of the Gates Foundation.*

.....  
.....

### ***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

.....  
.....

## **WHO & Regional Offices** [to 01 Mar 2025]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

28 February 2025 *News release*

**[Recommendations announced for influenza vaccine composition for the 2025–2026 northern hemisphere influenza season](#)**

28 February 2025 *Joint News Release*

**[New WHO and ITU standard aims to prevent hearing loss among gamers](#)**

28 February 2025 *Joint News Release*

**[Humanitarian access improves quality of polio vaccination campaign in the Gaza Strip](#)**

27 February 2025 *Statement*

**[Third meeting of the International Health Regulations \(2005\) Emergency Committee regarding the upsurge of mpox 2024 – Temporary recommendations](#)**

26 February 2025 *News release*

**[WHO strengthens support for grassroots crowdsourcing campaign: a global movement of unity and solidarity](#)**

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: 18 February 2025

**[Uganda discharges all eight Ebola disease patients](#)**

:: 18 February 2025

**[Scaling up mpox outbreak response in Sierra Leone](#)**

:: 17 February 2025

**[Protecting the Central African Republic's remote communities from polio](#)**

:: 14 February 2025

### **WHO Region of the Americas PAHO**

:: 21 Feb 2025

**[PAHO and AECID Strengthen Health Cooperation, Focusing on Cervical Cancer Elimination in the Americas](#)**

Washington, DC, February 21, 2025 (OPS) – The Pan American Health Organization (PAHO) and the Spanish Agency for International Development Cooperation (AECID) have formalized a memorandum of understanding to reinforce their shared commitment to improving public health across the Americas. This agreement marks a decisive step in the fight against...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

:: 17 February 2025 *News release*

**[New WHO/Europe report shows mixed picture in response and recovery during the COVID-19 transition period](#)**

### **WHO Eastern Mediterranean Region EMRO**

:: [Mass polio vaccination campaign to continue in the Gaza Strip](#)

19 February 2025

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

### **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

### **Weekly Epidemiological Record**

**Vol. 100, No. 09, pp. 61–74 28 February 2025**

<https://iris.who.int/bitstream/handle/10665/380670/WER10009-eng-fre.pdf>

- WHO's Health Emergencies Programme: acute emergencies monthly summary – January 2025
- Summary report of the 26th meeting of the WHO Advisory Committee on Variola Virus Research

.....

### **New WHO Publications**

<https://www.who.int/publications>

*Selected*

28 February 2025

[Report of the WHO consultation on asymptomatic tuberculosis, Geneva, Switzerland, 14-15 October 2024](#)

26 February 2025

[Interim guidance on strengthening community detection and response during the mpox outbreak, 25 February...](#)

26 February 2025

[WHO SEAR 4th Epidemiological Bulletin 2025](#)

24 February 2025

[WHO global water, sanitation and hygiene: annual report 2023](#)

.....

.....

**USA – HHS, FDA, CDC+**

### **Editor's Note:**

*We employ bolded red text below to identify observations we assess might be useful to readers.*

### **HHS**

#### News

*No new digest content identified.*

### **FDA**

#### Press Announcements

**[FDA Roundup: February 28, 2025](#)**

### **FDA VRBPAC**

#### Advisory Committee Calendar

***The Advisory Committee calendar does not list any future scheduled meetings of any FDA advisory committee, including VRBPAC.***

### **CDC/ACIP [U.S.] [to 01 Mar 2025]**

<http://www.cdc.gov/media/index.html>

#### Latest News

#### **[CDC Statement on Measles Outbreak](#)**

CDC is in close communication with Texas health authorities over the recent measles outbreak. Feb 27, 2025

CDC continues to be in close communication with Texas health authorities about the measles outbreak in West Texas, following the death of a child. HHS sends its deepest condolences to the family. HHS is providing technical assistance, laboratory support, vaccines, and therapeutic medication as needed to the Texas Department of State Health Services and New Mexico Department of Health, which are leading the responses to the outbreaks in their jurisdictions.

Measles outbreaks are occurring globally, particularly in Asia, which means that there is an increased likelihood of cases among unvaccinated travelers returning to the U.S., which we saw in the February 19 case of an Orange County, California resident returning from Asia. Vaccination remains the best defense against measles infection. Measles does not have a specific antiviral treatment. Supportive care, including vitamin A administration under the direction of a physician, may be appropriate.

HHS Secretary Kennedy has spoken directly to Governor Abbott, Commissioner of the Texas Department of State Health Services Dr. Jennifer A. Shuford, and other public health officials to express HHS' willingness to support local efforts in dealing with the outbreak.

### **ACIP Meetings** [to 01 Mar 2025]

#### Next ACIP Meeting

#### **[ACIP Meeting February 26-28, 2025 Postponed](#)**

The ACIP meeting will be postponed to accommodate public comment in advance of the meeting. The ACIP workgroups met as scheduled this month and will present at the upcoming ACIP meeting.

#### Agenda for February 26-28

***[Agenda appears stable from earlier agenda versions]***

### **National Vaccine Program**

<https://www.hhs.gov/vaccines/about/index.html>

#### Upcoming Meetings/Latest Updates

***No 2025 meeting dates posted.***

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2024.html>

MMWR Weekly, January 16, 2025 / No. 2



[PDF of this issue](#)

- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025](#)
- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025](#)

***The January 16th MMWR which we carried in an earlier edition no longer appears on the MMWR webpage.*** We note the two ACIP recommended immunization schedules that comprise this edition. The PDF link below is still active.

.....  
.....

## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### [Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 24-27 February 2025](#)

Four new medicines recommended for approval; another 16 medicines recommended for extension of their therapeutic indications  
28 February 2025

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*News*

#### [No evidence that the novel coronavirus identified in bats can be transmitted to humans](#)

25 Feb 2025

*Surveillance and monitoring*

#### [Surveillance report on interim COVID-19 vaccination coverage in the EU/EEA, August 2024 – January 2025](#)

27 Feb 2025

This report presents a description of COVID-19 vaccine coverage in the EU/EEA between 1 August 2024 and 17 January 2025, with some variation in dates between countries.

.....  
.....

### Africa CDC [to 01 Mar 2025]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

#### [Moving forward the vaccine supply chain in Africa](#)

1 March 2025

... Recently published [CEPI-funded research](#) conducted by The MindCo interviewed multiple existing African vaccine manufacturers and suppliers of input materials to determine what mid-to-long-term solutions could be implemented to support vaccine manufacturing in Africa. The work is intended to inform the Platform for Harmonized African Health Products Manufacturing, set up by Africa CDC to reach its 60% goal...

*Press Releases*

## **[Africa CDC's Emergency Consultative Group Recommends Continuation of Mpox as a Public Health Emergency of Continental Security](#)**

28 February 2025

Addis Ababa, Ethiopia | 28 February 2025 – The Emergency Consultative Group (ECG) of the Africa Centres for Disease Control and Prevention (Africa CDC), chaired by Professor Salim Abdool Karim, has unanimously recommended the continuation of Mpox as a Public Health Emergency of Continental Security (PHECS). This decision follows a comprehensive review of the ongoing outbreak, highlighting rising case numbers, continued spread to new countries, the emergence of a highly transmissible new variant, and persistent challenges in vaccine supply and distribution...

*Stories*

## **[Regional Networks to Strengthen Africa's Vaccine and Health Products Manufacturing Workforce](#)**

26 February 2025

In a move to accelerate Africa's capacity to produce its own vaccines and other health products, the Africa Centres for Disease Control and Prevention (Africa CDC) has established Regional Capability and Capacity Networks (RCCNs) to drive skills development, workforce training and R&D...

.....

### **China CDC+**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China** [to 01 Mar 2025]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC** [to 01 Mar 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

### **China CDC**

#### **[CCDC Weekly Reports: Current Volume \(7\)](#)**

2025-02-28 / No. 9

[View PDF of this issue](#)

*No new digest content identified.*

.....

.....

### ***[Contents \[click to move among sections\]](#)***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 01 Mar 2025]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 01 Mar 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

**[Mark Suzman's Statement on UK Decision to Cut Foreign Aid](#)**

*Statement Feb 25, 2025*

The British public have always shown their compassion and support for the world's poorest people, especially in times of crisis. The cuts that have been announced are deeply regrettable and will harm the most vulnerable people around the world. The Gates Foundation and successive UK Governments have worked together for over twenty years to ensure our joint funding saves as many lives as possible. It is now more important than ever that the aid budget that remains goes to the people that need it most.

**Bill & Melinda Gates Medical Research Institute** [to 01 Mar 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 01 Mar 2025]

<https://carb-x.org/>

*News*

02.26.2025 |

**[CARB-X launches 2025 Funding Round targeting global infectious disease threats](#)**

CARB-X announces 2025 Funding Round seeking therapeutics for infections caused by Gram-negative pathogens and diagnostics for Salmonella Typhi

02.25.2025 |

**[CARB-X funds Immunetep to develop vaccine to prevent E. coli infections](#)**

CARB-X will award \$2 million to Immunetep to develop a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli.

**Chan Zuckerberg Initiative** [to 01 Mar 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 01 Mar 2025]

<http://cepi.net/>  
*CEPI News, Blog*  
News

**[CEPI, Brown and NTI partner with rising leaders to take biological threats off the table](#)**

23 Feb 2025

The Coalition for Epidemic Preparedness Innovations (CEPI), the Brown Pandemic Center, and the Nuclear Threat Initiative (NTI) jointly endorse the Biosecurity Rising Leaders' Munich Security Conference Declaration: *Taking Biological Threats off the Table Through Next Generation Global South Leadership*.

*Blog*

**[Moving forward the vaccine supply chain in Africa](#)**

23 Feb 2025

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 01 Mar 2025]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 01 Mar 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [to 01 Mar 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 01 Mar 2025]

<https://dukeghic.org/>

*News*

**[Issue 8: 24 February 2025 | Mpox: Transparency and Accountability for the Global Response](#)**

February 24, 2025

Welcome to the eighth issue of our report, "Mpox: Transparency and Accountability for the Global Response." In this edition, we provide a comprehensive update on the latest developments a...

**EDCTP** [to 01 Mar 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*No new digest content identified.*

**Emory Vaccine Center** [to 01 Mar 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 01 Mar 2025]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Fondation Merieux** [to 01 Mar 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 01 Mar 2025]

<https://www.gavi.org/>

*Press Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 01 Mar 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – February 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 21 Feb 2025](#)

**GHIT Fund** [to 01 Mar 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 01 Mar 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 01 Mar 2025]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 01 Mar 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 01 Mar 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 01 Mar 2025]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 01 Mar 2025]

<https://www.iavi.org/>

*Press Releases*

**[IAVI and Biofabri/Zendal announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy trial of the tuberculosis vaccine candidate MTBVAC](#)**

February 26, 2025

MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial for the prevention of TB disease in adolescents and adults with latent TB infection in South Africa, Kenya, and Tanzania.

**INSERM** [to 01 Mar 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 01 Mar 2025]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 01 Mar 2025]

<https://www.icrc.org/en/whats-new>

*Latest press releases and statements [Selected]*

*Statement*

**ICRC president: Human life must transcend political divides – both in war and in peacetime**

25 February 2025

Speech given by Mirjana Spoljaric, President of the International Committee of the Red Cross, at the 58th session of the Human Rights Council

*Statement*

**"The world cannot afford ever-escalating wars:" A call to revive political commitment to international humanitarian law**

24 February 2025

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 01 Mar 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 27/02/2025*

**Red Cross calls for urgent funding to meet growing humanitarian needs in DRC**

*Press release 26/02/2025*

**Red Cross launches an appeal to respond to Uganda's Eighth Ebola outbreak**

**IPPS - International Pandemic Preparedness Secretariat** [to 01 Mar 2025]

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

**Institut Pasteur** [to 01 Mar 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press release 26.02.2025*

**Argobio and the Institut Pasteur launch Enodia Therapeutics: A biotech company with a new approach for Targeted protein Degradation**

**ISC / International Science Council** [to 01 Mar 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

**Eight distinguished individuals join the ISC Governing Board**

The ISC Governing Board has been reconstituted and re-energized at a critical moment for science and society globally.

February 25, 2025

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**19th International Congress of Immunology**

Vienna, August 17-22, 2025.

**IVAC** [to 01 Mar 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

**Preventing Cancer: The Far-Reaching Impact of Vaccines**

February 24, 2025

**IVI** [to 01 Mar 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

**Korean Epidemiologists Team Up with Global Epidemiologists: A conversation with fellows from the Korea Disease Control and Prevention Agency**

*[Undated]*

**IVI Biorepository opens as a global center for biological resources to advance infectious disease preparedness**

February 21, 2025,

New state-of-the-art facility to serve as vital infrastructure for research collaboration to accelerate the development of vaccines, diagnostics, and therapeutics Capable of sustainably and systematically preserving up to 4 million samples including pathogens and biospecimens

**Johns Hopkins Center for Health Security** [to 01 Mar 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 01 Mar 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Democratic Republic of Congo*

**MSF adjusts emergency response around Goma amid mass departures from displacement camps**

Project Update 27 Feb 2025

*Conflict in Sudan*

**Sudan: MSF forced to halt activities as violence engulfs Zamzam camp in North Darfur**

Press Release 24 Feb 2025

**National Academy of Medicine - USA** [to 01 Mar 2025]

<https://nam.edu/programs/>



*News [Selected]*  
*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]- USA** [to 01 Mar 2025]

<https://www.nationalacademies.org/newsroom>

*News*

*No new digest content identified.*

**NIH** [to 01 Mar 2025]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**PATH** [to 01 Mar 2025]

<https://www.path.org/media-center/>

*Newsroom*

**[Zambia and Nigeria take bold steps toward strengthening health products regulation in Africa](#)**

February 26, 2025 by PATH

**[Report on medical oxygen finds a 70 percent coverage gap and calls for action to end suffering and death](#)**

February 25, 2025 by PATH

New report by The Lancet Global Health Commission on Medical Oxygen Security spotlights critical medical oxygen gaps and proposes recommendations to strengthen health systems toward universal oxygen access.

**Sabin Vaccine Institute** [to 01 Mar 2025]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 01 Mar 2025]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Feature story*

**[Impact of US funding freeze on the global AIDS response — Weekly update](#)**

26 February 2025

Sixteen new reports on the impact of the freeze of US foreign assistance on the global AIDS response were received from UNAIDS' Country Offices during the week of 17-21 February. As of 21 February, at least one status report had been received from 55 countries, including 42 PEPFAR-supported and 13 that receive some US support.

Reports received over the past week show that waivers have led to the resumption of select clinical services, such as HIV treatment and prevention of vertical transmission, in many countries that are highly dependent on US funding. However, the durability of this resumption is unclear amid multiple reports that key US government systems and staff responsible for paying implementing partners are either offline or working at greatly reduced capacity...

**UNICEF** [to 01 Mar 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Press release 27 February 2025*

**[Cholera surges in Sudan's White Nile State, more than 292,000 children at risk in Kosti](#)**

PORT SUDAN, 27 February 2025 – More than 500 children are among the 2,700 cholera cases, that have been reported in Sudan's White Nile State between 1 January and 24 February 2025, according to health authorities. The outbreak has already killed at least 65 people including ten children. In response, UNICEF, toget...

**Unitaid** [to 01 Mar 2025]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 01 Mar 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 01 Mar 2025]

<https://www.vaccineacceptance.org/>

*News*

**[Integrating Nutrition and Vaccination Efforts in Crisis-Affected Regions of Cameroon](#)**

February 28, 2025

**Vaccine Confidence Project** [to 01 Mar 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 01 Mar 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 01 Mar 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*No new digest content identified*

**The Wistar Institute** [to 01 Mar 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

February 28, 2025

**The Wistar Institute Discovers a Promising Target in Brain Cancer**

PHILADELPHIA — (Feb. 28, 2024) — The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells...

**World Bank** [to 01 Mar 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 01 Mar 2025]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**World Medical Association [WMA]** [to 01 Mar 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health [OIE]** [to 01 Mar 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....  
.....

**ARM [Alliance for Regenerative Medicine]** [to 01 Mar 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 01 Mar 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 01 Mar 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [to 01 Mar 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 01 Mar 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*No new digest announcements identified.*

**International Alliance of Patients' Organizations – IAPO** [to 01 Mar 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

**[IAPO statement on recent decisions affecting global health](#)**

Wednesday, 26 February 2025

The recent decisions by the United States (U.S.) to withdraw from the World Health Organization (WHO), freeze existing foreign aid, and pull the country out of the United Nations Human Rights Council have sent shockwaves across the global health community...

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

**[Harmonising Bioequivalence: Advancing Global Access to Generic Medicines \(February 2025\)](#)**

The 3rd Bioequivalence Conference, co-hosted by the International Generic and Biosimilar Medicines Association (IGBA) and Medicines for Europe, concluded today at the Hilton Amsterdam Airport Schiphol Hotel, The Netherlands. This landmark event brought together experts from regulatory authorities, industry, and academia to discuss the evolving bioequivalence landscape and its critical role in improving global access to medicines.

**PhRMA** [to 01 Mar 2025]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

**AstraZeneca**

*Press Releases* - *No new digest content identified.*

**Bavarian Nordic**

*Latest News*

February 28, 2025

**[Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older](#)**

*First chikungunya vaccine approved in Europe for persons as young as 12 years old.  
On track for launch in key European markets in the first half of 2025.*

February 25, 2025

**Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine**

*Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries.*

**Bharat Biotech**

Press Releases - No new digest announcements identified

**BioCubaFarma – Cuba**

Últimas Noticias - No new digest announcements identified

**Biological E**

News

**BIOLOGICAL E. LIMITED PARTNERS WITH BAVARIAN NORDIC TO INCREASE GLOBAL ACCESS TO CHIKUNGUNYA VACCINE**

*The manufacturing agreement is the first step in working together to provide Chikungunya Vaccine to low-and middle-income countries*

*The initial technology transfer will be followed by commercial manufacturing, which has the potential to generate up to 300 new jobs at BE*

Hyderabad, February 25, 2025

**BioNTech**

Press Releases - No new digest announcements identified

**Boehringer**

Press Releases

**Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis**

Ingelheim, Germany, Thu, 20/02/2025 - 14:00

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)<sup>[1]</sup> and OXB,<sup>[2]</sup> today announce the start of LENTICLAIR™ 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene therapy aiming to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease. The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis transmembrane conductance regulator (CFTR) modulators.<sup>[i]</sup>

**CanSinoBIO**

News - Website not responding at inquiry

**CIGB**

Latest News - No new digest announcements identified.

**CinnaGen**

Recent News - No new digest announcements identified.

**Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

**Curevac**

News - No new digest announcements identified.

**Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

**GSK**

Press releases for media - No new digest announcements identified.

**EuBiologics, S Korea**

News - No new digest announcements identified.

**IMBCAMS, China**

Home - Website not responding at inquiry.

**JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

**Merck**

News releases - No new digest announcements identified

**Moderna**

Press Releases

February 28, 2025

[Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine](#)

**Nanogen**

News - No new digest announcements identified

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases - No new digest announcements identified

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Sanofi Pasteur**

Press Releases - No new digest announcements identified.

**Serum Institute**

News & Announcements - No new digest announcements identified.

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

## **Sinovac**

Press Releases - No new digest announcements identified.

## **SK Biosciences**

Press Releases

### **[SK bioscience Secures Additional PAHO Contract to Supply Varicella Vaccines to Latin America](#)**

SKYVaricella®, supplied to Latin America since 2022 through PAHO, secures an additional three-year  
2025.02.28

### **[SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate](#)**

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Z...  
2025.02.25

## **Takeda**

Newsroom - No new digest announcements identified.

## **Valneva**

Press Releases

February 28, 2025

### **[Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®](#)**

## **Vector State Research Centre of Virology and Biotechnology**

Home - [Website not responding [404 error]]

## **WestVac Biopharma**

Media - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but

indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 27, Number 2: E67-166 Feb 2025

<https://journalofethics.ama-assn.org/issue/pain-management-non-labor-and-delivery-obgyn-procedures>

***Issue Theme: Pain Management in Non-Labor and Delivery OBGYN Procedures***

### **American Journal of Human Genetics**

Feb 06, 2025 Volume 112 Issue 2 p199-456

<https://www.cell.com/ajhg/current>

#### **This month in The Journal**

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Many tools developed for genome-wide analyses perform best in cohorts of a single ancestry group. The genomes of admixed populations contain segments from different ancestry groups and vary from person to person. These features present challenges to investigators who would like to expand the depth, breadth, and diversity of their studies. One approach to control for population structure in admixed populations is local ancestry interference (LAI). By assigning ancestry groups to discrete genomic regions, LAI can boost the power of multiple genomic analyses.

### **American Journal of Infection Control**

February 2025 Volume 53 Issue 2 p175-284

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

February 2025 Volume 68 Issue 2 p217-428

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

February 2025 115(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 2 (Feb 2025)



<https://www.ajtmh.org/view/journals/tpmd/112/2/tpmd.112.issue-2.xml>

*Research Article*

**[Understanding the Challenges of Advocacy Communication, Social Mobilization, and Operationalization for COVID-19 and Routine Immunization in Nigeria](#)**

Saheed Isiaka, et al.

DOI: <https://doi.org/10.4269/ajtmh.24-0282>

*Research Article*

**[Human-Centered Design to Respond to Public Health Crises: Maintaining Canine Rabies Vaccination during the COVID-19 Pandemic in Peru](#)**

Ricardo Castillo-Neyra, et al.

DOI: <https://doi.org/10.4269/ajtmh.24-0308>

**Annals of Internal Medicine**

February 2025 Volume 178, Issue 2

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 339 February 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/339/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 01 Mar 2025)

[No new digest content identified]

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 01 Mar 2025)

**[Uptake, scale up, integration of vaccine, immunization, and health supply chain management technologies and innovation into policy: experience from Tanzania](#)**

*The uptake, scale-up, and integration of technologies and innovations have been the emphasis of the government of Tanzania for sustained health systems strengthening. This study sought to assess the state and ...*

Authors: Henry A. Mollel, Lawrence D. Mushi and Richard V. Nkwera

Citation: *BMC Health Services Research* 2025 25:306

Content type: Research Published on: 25 February 2025

**BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 01 Mar 2025)

[No new digest content identified]

**BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>  
(Accessed 01 Mar 2025)

#### **[How have PHEIC determinations changed since the COVID-19 pandemic? A document analysis of 101 WHO International Health Regulations Emergency Committees' statements](#)**

*The World Health Organization (WHO) is chiefly responsible for declaring a Public Health Emergency of International Concern (PHEIC). The WHO makes the assessment on whether to declare a formal PHEIC if the eve...*

Authors: Kevin Hemmat, Michelle Amri and Daniel Eisenkraft Klein

Citation: BMC Public Health 2025 25:818

Content type: Research Published on: 28 February 2025

#### **[Trust in official information as a key predictor of COVID-19 vaccine acceptance: evidence from a Czech longitudinal survey study](#)**

*COVID-19 vaccine hesitancy (CVH) has become a critical public health issue, with attitudes toward vaccines emerging as a broader social issue. Public debates surrounding vaccines have expanded beyond health co...*

Authors: Dominika Grygarová, Jiří Kožený, Lýdie Tišanská, Marek Havlík and Jiří Horáček

Citation: BMC Public Health 2025 25:770

Content type: Research Published on: 25 February 2025

#### **[Predictors of willingness of HPV vaccine uptake across Eight States in Nigeria](#)**

*The Nigerian Federal Government planned to launch the Human Papillomavirus (HPV) vaccine on September 25, 2023. We therefore aimed to assess caregiver awareness and willingness regarding HPV vaccine uptake for...*

Authors: Hilary I. Okagbue, Grace Erekosima, Sidney Sampson, Brian Atuhaire, Olugbemisola Samuel, Bright Chimezie, Mahfus Dauda, Akolade Jimoh, Gideon Ogbu, Joshua Ayuba and Iveren Shinshima

Citation: BMC Public Health 2025 25:745

Content type: Research Published on: 24 February 2025

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

**BMJ Evidence-Based Medicine**

February 2025 - Volume 30 - 1

<https://ebm.bmj.com/content/30/1>

[Reviewed earlier]

**BMJ Global Health**

February 2025 - Volume 10 - 2

<https://gh.bmj.com/content/10/2>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 103, Number 1, January 2025, 1-80

<https://www.who.int/publications/journals/bulletin/>

[\*In this month's Bulletin\*](#)

In the editorial section, Katherine Littler et al. (2) call for papers for a special theme issue on the ethics of research into health and climate change.

Gary Humphreys (5–6) reports on initiatives to mitigate unintended consequences of health policies. Glenda Gray talks to Humphreys (7–8) about her career working on HIV prevention and treatment.

[Reviewed earlier]

**Cell**

Feb 06, 2025 Volume 188 Issue 3 p573-868

<https://www.cell.com/cell/current>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 51, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

**Clinical Pharmacology & Therapeutics**

Volume 117, Issue 3 Pages: 599-857 March 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New issue; No digest content identified]

**Clinical Therapeutics**

March 2025 Volume 47 Issue 3 p179-248

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

**Clinical Trials**

Volume 22 Issue 1, February 2025

<https://journals.sagepub.com/toc/ctja/22/1>

*Open Access Research article* First published June 19, 2024

**[A survey on UK researchers' views regarding their experiences with the de-identification, anonymisation, release methods and re-identification risk estimation for clinical trial datasets](#)**

Aryelly Rodriguez, et al.

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 01 Mar 2025]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 149 February 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/149/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 8, Issue 1 / February 2025

<https://www.liebertpub.com/toc/crispr/8/1>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

**Current Medical Research and Opinion**

Volume 41, Issue 1 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 01 Mar 2025]

[No new digest content identified]

**Developing World Bioethics**

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

### **Development Policy Review**

Volume 43, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

### **Disasters**

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

### **EMBO Reports**

Volume 26 Issue 3 10 February 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 31, Number 2—February 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Moral distress in clinical research • Research with incarcerated and homeless women***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>

[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

*Special Section*

***Will Trump Change the World?***

### **Forum for Development Studies**

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 01 Mar 2025]

[No new digest content identified]

### **Gene Therapy – Nature**

Volume 32 Issue 1, January 2025

<https://www.nature.com/gt/volumes/32/issues/1>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 27, Issue 2 February 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/2>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 01 Mar 2025]

[No new digest content identified]

### **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 01 Mar 2025]

[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 01 Mar 2025]

[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 40, Issue 2, March 2025

<https://academic.oup.com/heapol/issue/40/2>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 01 Mar 2025]

[No new digest content identified]

### **Human Gene Therapy**

Volume 36, Issue 3-4 / February 2025

<https://www.liebertpub.com/toc/hum/36/3-4>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

### **Immunity**

Feb 11, 2025 Volume 58 Issue 2 p265-514

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 01 Mar 2025]

[No new digest content identified]



### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 01 Mar 2025]

[No new digest content identified]

### **International Health**

Volume 17, Issue 1, January 2025

<https://academic.oup.com/inthealth/issue/17/1>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 2 (2025): February 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/121>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 53, Issue 6, December 2024

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

*Table of contents*

[Reviewed earlier]

### **JAMA**

February 25, 2025, Vol 333, No. 8, Pages 647-732

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

#### **[Consequences and Opportunities From Poor Uptake of COVID Vaccinations Despite Strong Evidence](#)**

Robert M. Califf, MD

*JAMA*. 2025;333(8):659-660. doi:10.1001/jama.2025.0255

This Viewpoint examines poor uptake of the annual updated COVID vaccines among US residents despite strong evidence of their effectiveness in lowering the risk of death, serious illness, and hospitalization.

#### **[Host-Directed Therapy in Pandemic Preparedness](#)**

Mihai G. Netea, MD, PhD; Frank L. van de Veerdonk, MD, PhD; Evangelos J. Giamarellos-Bourboulis, MD, PhD

JAMA. 2025;333(8):661-662. doi:10.1001/jama.2024.26152

This JAMA Viewpoint explores the addition of host-directed therapy using immunotherapeutic agents to pandemic preparedness programs.

### **Protecting Privacy When Genetic Databases Are Commercialized**

Anya E. R. Prince, JD; Kayte Spector-Bagdady, JD, MBE

JAMA. 2025;333(8):665-666. doi:10.1001/jama.2024.26279

This Viewpoint questions whether people's health data obtained in direct-to-consumer genetic testing can be used, shared, or marketed in the future.

### **JAMA Health Forum**

February 2025, Vol 6, No. 2

<https://jamanetwork.com/journals/jama-health-forum/issue>

*JAMA Forum*

### **Recognizing and Strengthening the 4 Pillars of US Childhood Vaccine Policy**

Joshua M. Sharfstein, MD; Sarah Despres, JD

open access

JAMA Health Forum. 2025;6(2):e250363. doi:10.1001/jamahealthforum.2025.0363

This JAMA Forum discusses Trump administration nominations for the secretary of the Department of Health and Human Services and the director of the Centers for Disease Control and Prevention, their positions on childhood vaccines, and provides information on the 4 pillars of the US childhood vaccine effort.

### **JAMA Pediatrics**

February 2025, Vol 179, No. 2, Pages 111-224

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

### **JB I Evidence Synthesis**

February 2025 - Volume 23 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

*Contents*

[New issue; No digest content identified]

### **Journal of Community Health**

Volume 50, Issue 1 February 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-1>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 173 March 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/173/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: 20th Anniversary Forum***

[Reviewed earlier]

### **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

*Table of Contents*

[Reviewed earlier]

### **Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

[Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

### **Journal of International Development**

Volume 37, Issue 1 Pages: 1-349 January 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

### **Journal of Medical Ethics**

February 2025 - Volume 51 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 277 February 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>

[Reviewed earlier]

### **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Public Health Policy**

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

February 2025 Volume 22 Issue 223

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 32, Issue 1, January 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 98 Number 12 December 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Mar 01, 2025 Volume 405 Number 10480 p671-754

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

#### **H5N1 avian influenza: technical solutions, political challenges**

The Lancet

It has been almost 1 year since the detection of an unprecedented spread of highly pathogenic avian influenza A(H5N1) in dairy cows in the USA. Although there is still no evidence of human-to-human transmission and human deaths have been rare, concern over the potential impacts on human health remains high. **The B3.13 genotype has predominated in cattle and human beings, causing largely mild disease, but there have been worrying recent developments.** In the past couple of months a new genotype, D1.1, resulted in the death of a person in Louisiana—the first death in the USA from H5N1—while a teenager in Canada was critically ill for several months. On Jan 31, the US Department of Agriculture announced the first detection of D1.1 in dairy cattle in Nevada, followed by another independent introduction in Arizona. The risk to the general public is still considered low, but the range and sustained infection of mammals, seemingly independent spillover between species, and potential for severe disease, demand urgent action. Animal welfare, public health, and commercial trade are at stake.

**The Food and Agriculture Organization and World Organisation for Animal Health have published a new 10-year global strategy for avian influenza which calls for better surveillance, data collection and sharing, protection of poultry through biosecurity, vaccination of birds, zoning and compartmentalisation,** and other changes to poultry production to reduce the risk of infection and transmission, all under the rubric of One Health. This will require enhanced surveillance, diagnostics, and laboratory capacity, as well as the rollout of medical countermeasures and changes to agricultural practices and cultures. These are important technical solutions, but there are substantial political challenges.

In the USA, the centre of the epidemic, Gerald Parker, a bird flu expert, veterinarian, and former top-ranking health official, has been appointed to lead the White House's Pandemic Office, while the country's first national One Health plan was published in January. Appointing a competent leader and formulating plans is all very well, but the country also needs the technical expertise, workforce, infrastructure, and data to do the work of detecting, preventing, and responding to infection. Essential

public health and scientific institutions are being gutted, with research funding cut and the sharing of data stymied. The Department of Agriculture has been scrambling to rehire staff working on the federal avian influenza response who were fired in sweeping cuts. The new Secretary of State for Health and Human Services, Robert F Kennedy Jr, has previously said that he would instruct the NIH to take “a break” from infectious diseases.

**Negotiations on the much-delayed pandemic preparedness treaty continued in Geneva last week, with concern still over how effective its language may be—if any is agreed at all.**

Although many national and supranational agencies across human, animal, and environmental health have already been working together on avian influenza in the spirit of One Health, an effective binding treaty could formalise responsibilities and establish obligations. Yet some countries see One Health as code for actions that will harm their livestock industries. Better surveillance is needed, but reporting of infections leads to culling. Vaccination of livestock is banned in many countries and can affect international trade. The USA and Canada have only recently eased a ban on French poultry after vaccination of ducks against bird flu with concerns that vaccination might mask infections. How can these perverse incentives be changed? Certainly, the economic costs of failing to contain infection are substantial. 41·4 million birds were culled because of influenza exposure over December and January in the USA. As of November, 2024, the US Government has spent \$1·25 billion in indemnity and compensation payments to farmers and egg prices have soared. And there are examples of how farming practices can be changed in the face of commercial pressures, to prioritise animal and human health. In response to concern over rising antimicrobial resistance, several countries have introduced policies and legislation to reduce antibiotic consumption in animals, despite the immediate commercial benefits of liberal use of antibiotics.

**The technical solutions for lessening the risk of zoonoses from food animals are known but putting them into practice comes with substantial political and economic hurdles.** Unless those challenges are confronted and overcome, then we will struggle to make a substantial impact on the risk of avian influenza, or any other potential pandemic, spreading and evolving further.

**The Lancet Child & Adolescent Health**

Feb 2025 Volume 9 Number 2 p77-150, e1-e3

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Feb 2025 Volume 7 Number 2 e103-e166

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Feb 2025 Volume 13 Number 2 e172-e371

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Feb 2025 Volume 25 Number 2 p135-242, e60-e113

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Feb 2025 Volume 10 Number 2 e71-e164

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Feb 2025 Volume 13 Number 2 p101-188, e9-e16

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 29, Issue 2 February 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-2>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 45 Issue 2, February 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Molecular Therapy**

Feb 05, 2025 Volume 33 Issue 2 p423-824

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

**Nature**

Volume 638 Issue 8052, 27 February 2025

<https://www.nature.com/nature/volumes/638/issues/8052>

*Editorial* 18 Feb 2025

[\*\*Learn COVID pandemic lessons — before it's too late\*\*](#)

Five years after the start of the COVID-19 pandemic, public weariness and irresponsible politics are hampering an effective response to global infectious-disease outbreaks.

**Nature Biotechnology**

Volume 43 Issue 2, February 2025

<https://www.nature.com/nbt/volumes/43/issues/2>

[Reviewed earlier]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 01 Mar 2025)

[Reviewed earlier]

### **Nature Genetics**

Volume 57 Issue 2, February 2025

<https://www.nature.com/ng/volumes/57/issues/2>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 9 Issue 1, January 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/1>

[Reviewed earlier]

### **Nature Medicine**

Volume 31 Issue 2, February 2025

<https://www.nature.com/nm/volumes/31/issues/2>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 24 Issue 2, February 2025

<https://www.nature.com/nrd/volumes/24/issues/2>

*Comment* 15 Jan 2025

#### **[Outlook for medicines development and use in 2025](#)**

Oncology innovations, obesity medicines, an uptick for mergers and acquisitions, regulation for artificial intelligence applications and growing consumerization are expected to be key topics.

Sarah Rickwood, Helena Bayley, Markus Gores

*Review Article* 02 Dec 2024

#### **[Vaccines for cancer prevention: exploring opportunities and navigating challenges](#)**

Cancer-preventive vaccines can reduce cancer occurrence by inducing a specific immune response against tumours before they can fully develop. This Review discusses results from pioneering clinical studies and potential approaches to design potent prophylactic cancer vaccines in the future.

Michele Graciotti, Lana E. Kandalaft

### **Nature Reviews Genetics**

Volume 26 Issue 2, February 2025

<https://www.nature.com/nrg/volumes/26/issues/2>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 25 Issue 2, February 2025

<https://www.nature.com/nri/volumes/25/issues/2>



*Perspective* 24 Sept 2024

### **Understanding vertebrate immunity through comparative immunology**

Technological advances in cellular and molecular immunology are providing unprecedented new insights into evolutionary immunology. This Perspective highlights new insights into the immune systems of different vertebrate species and discusses emerging general principles of immune system function.

Thomas Boehm

### **New England Journal of Medicine**

Volume 392 No. 9 February 27, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

### **Highly Pathogenic Avian Influenza A(H5N1) Virus Infections in Humans**

S. Garg and Others

*Editorials*

### **The Emerging Threat of H5N1 to Human Health**

M.G. Ison and J. Marrazzo

### **NEJM Evidence**

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 01 Mar 2025]

*Review Article* Published: 01 March 2025

### **Recent advances and perspectives on the development of circular RNA cancer vaccines**

Zhaohui Gong, et al.

*Abstract*

Engineered circular RNAs (circRNAs) are emerging as promising platforms for RNA-based vaccines in cancer treatment. We summarize the recent advances of design, synthesis, and delivery of circRNA-based cancer vaccines, and highlight the applications and challenges of circRNA vaccines in cancer therapy. Further enhancements are required in areas such as antigen selection, targeted delivery, multidimensional crosstalks, and clinical trial assessments to advance the efficacy and safety of circRNA vaccines in cancer.

### **Pediatrics**

Volume 155, Issue 2 February 2025

<https://publications.aap.org/pediatrics/issue/155/2>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 43, Issue 3 March 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>  
[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)  
(Accessed 01 Mar 2025)

#### **[Understanding the vaccine hesitancy of COVID-19 in Benin](#)**

Daleb Abdoulaye Alfa, Jean-Yves Le Hesran, Inès Boko, Anani Agossou, Aurore Atchadé, Marc Fiogbé, Emmanuel Yovo, Sandrine Hounsa, Achille Massougboji, Gilles Cottrell  
Research Article | published 25 Feb 2025 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0004267>

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 01 Mar 2025)  
[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>  
[Accessed 01 Mar 2025]  
[No new digest content identified]

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 01 Mar 2025]  
[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

March 4, 2025 | vol. 122 | no. 9

<https://www.pnas.org/toc/pnas/122/9>

[New issue; No digest content identified]

## **PNAS Nexus**

Volume 4, Issue 1, January 2025

<https://academic.oup.com/pnasnexus/issue/4/1>

[Reviewed earlier]

## **Prehospital & Disaster Medicine**

Volume 39 - Issue 6 - December 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 191 February 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

February 2025 Volume 292 Issue 2040

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

## **Public Health**

Volume 239 Pages 1-242 (February 2025)

<https://www.sciencedirect.com/journal/public-health/vol/239/suppl/C>

[Reviewed earlier]

## **Public Health Ethics**

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

## **Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

## **Public Health Reports**

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

**Qualitative Health Research**

Volume 35 Issue 2, February 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

**Research Ethics**

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 01 Mar 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

**Risk Analysis**

Volume 45, Issue 2 pages: 265-472 February 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 01 Mar 2025]

[No new digest content identified]

**Royal Society Open Science**

February 2025 Volume 12 Issue 2

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

**Science**

Volume 387| Issue 6737| 28 Feb 2025

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

**Science and Engineering Ethics**

Volume 31, Issue 1 February 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

[Reviewed earlier]

## **Science Translational Medicine**

Volume 17| Issue 787| 26 Feb 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

## **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 01 Mar 2025]

[No new digest content identified]

## **Social Science & Medicine**

Volume 365 January 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/365/suppl/C>

*Research article* Abstract only

**[Boundary-work in genomic medicine: Safeguarding the future of diagnostic next-generation sequencing in the clinic](#)**

Janneke M.L. Kuiper, Pascal Borry, Danya F. Vears, Ine Van Hoyweghen

Article 117498

*Research article* Open access

**[Structural violence as a driver of COVID-19 vaccine hesitancy and low vaccine uptake among people experiencing homelessness in Toronto, Canada: A qualitative study](#)**

J.I.R. Jenkinson, J. Wigle, L. Richard, T. Tibebu, ... S.W. Hwang

Article 117588

*Research article* Open access

**[Borrowing regulatory capacity in middle-income countries during public health crises: Brazil, regulatory reliance, and the politics of COVID-19 vaccine regulation](#)**

Elize Massard da Fonseca, Herschel S. Nachlis, Kyle Thomson, Holly Jarman

Article 117563

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 01 Mar 2025]

[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 63 January–February 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 30, Issue 2 Pages: i-iv, 71-142 February 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 49 7 March 2025

<https://www.sciencedirect.com/journal/vaccine/vol/49/suppl/C>

*Editorial No access*

**[COVID-19 in Canada: The Canadian COVID-19 experiences project and beyond](#)**

Helena C. Maltezou

Article 126821

*Short communication Open access*

**[Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023–2024 season in the Republic of Korea](#)**

So-Yeon Kim, Minju Song, Seunghyun Lewis Kwon

Article 126852

*Review article Abstract only*

**[A systematic review and meta-analysis on parental uptake and willingness to vaccinate children against human papillomavirus in the Eastern Mediterranean Region](#)**

Assem Gebreal, Rasha Ashmawy, Marafi Jammaa Ahmed, Maha Khattab, ... Ramy Mohamed Ghazy

Article 126832

*Research article Open access*

**[Historical analysis of the first smallpox vaccination campaigns in early 19-century northern Italy: organisation and communication insights for contemporary epidemics' prevention and control](#)**

Giacomo Pietro Vigezzi, Riccardo Vecchio, Chiara Barbati, Giulia Bonazza, ... Anna Odone

Article 126764

*Research article Open access*

**[Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries](#)**

Catherine Fleck-Vidal, Anna Doubell, Christiane Gerke, Usha Lamichhane, ... Laura Plant

Article 126771

*Research article Abstract only*

**[Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55–89 years from 1990 to 2021: Results from the global burden of disease study 2021](#)**

Yuxin Jiang, Yinsong Luo, Xi Xiao, Xiaorui Li, ... Jiaye Liu

Article 126786

*Research article Open access*

**What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis**

Ranju Baral, Kwame Amponsa-Achiano, Iracema Barros, Patience Cofie, ... Clint Pecenka  
Article 126769

*Research article Open access*

**How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic**

Mic McGoldrick, Tran Ba Quang Truong, Cristiana Campa, Murtuza Ali, ... Jennifer Eck  
Article 126782

**Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 01 Mar 2025]

*Open Access Review*

**The Influence of Financial Incentives on Vaccination Hesitancy: A Narrative Review of Recent Research**

by Jason Wong, Camrin Gill, Amir Abdo and Ava Eisa

Vaccines 2025, 13(3), 256; <https://doi.org/10.3390/vaccines13030256> - 28 Feb 2025

*Abstract*

Background: Vaccine hesitancy represents a significant global health challenge that greatly hinders public health efforts focused on managing the transmission of infectious diseases. A wealth of original research conducted worldwide has examined various incentives that could help alleviate vaccine hesitancy and increase vaccination [...]

*Open Access Editorial*

**Vaccination, Public Health and Health Communication: A Network of Connections to Tackle Global Challenges**

by Antonella Arghittu, Giovanna Deiana, Marco Dettori and Paolo Castiglia

Vaccines 2025, 13(3), 245; <https://doi.org/10.3390/vaccines13030245> - 27 Feb 2025

*Abstract*

Vaccination constitutes one of the most significant milestones in the history of Public Health [...]

*Open Access Review*

**Respiratory Vaccines in Older Adults: A Bibliometric Analysis and Future Research Agenda**

by Jose F. Parodi, Fernando Runzer-Colmenares, Carlos Cano-Gutiérrez, José Luis Dinamarca-Montecinos, Patricio Bendía-Gomez de La Torre, Paulo Fortes Villas Boas, Javier Flores-Cohaila, Diego Urrunaga-Pastor and Luis Miguel Gutiérrez-Robledo

Vaccines 2025, 13(3), 240; <https://doi.org/10.3390/vaccines13030240> - 26 Feb 2025

*Abstract*

Background/Objectives: Respiratory infections impact older adults due to immunosenescence and comorbidities, resulting in increased healthcare costs and mortality. While vaccination is a critical preventive measure, research on respiratory vaccines in older adults in Latin America and the Caribbean (LAC) remains underexplored.

*Open Access Systematic Review*

**Poliomyelitis in Nigeria: Impact of Vaccination Services and Polio Intervention and Eradication Efforts**

by Obinna V. Eze, Johanna C. Meyer and Stephen M. Campbell

Vaccines 2025, 13(3), 232; <https://doi.org/10.3390/vaccines13030232> - 25 Feb 2025

*Abstract*

Background: Polio is an infectious viral disease that can cause paralytic complications and death. Despite global efforts to eradicate wild poliovirus, there are ongoing outbreaks globally and the mutated form of paralytic polio, i.e., circulating vaccine-derived poliovirus, is present in Nigeria. Low [..

## Value in Health

February 2025 Volume 28 Issue 2 p175-322

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

## World Development

Volume 187 March 202

<https://www.sciencedirect.com/journal/world-development/vol/187/suppl/C>

[New issue; No digest content identified]

.....  
.....

### **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## **Pre-Print Servers**

### **arxiv**

<https://arxiv.org/>

[Accessed 01 Mar 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

[arXiv:2502.18864](https://arxiv.org/abs/2502.18864) (cross-list from cs.AI) [pdf, other]

### **[Towards an AI co-scientist](#)**

[Juraj Gottweis](#), [Wei-Hung Weng](#), [Alexander Daryin](#), [Tao Tu](#), [Anil Palepu](#), [Petar Sirkovic](#), [Artiom Myaskovsky](#), [Felix Weissenberger](#), [Keran Rong](#), [Ryutaro Tanno](#), [Khaled Saab](#), [Dan Popovici](#), [Jacob Blum](#), [Fan Zhang](#), [Katherine Chou](#), [Avinatan Hassidim](#), [Burak Gokturk](#), [Amin Vahdat](#), [Pushmeet Kohli](#), [Yossi Matias](#), [Andrew Carroll](#), [Kavita Kulkarni](#), [Nenad Tomasev](#), [Yuan Guan](#), [Vikram Dhillon](#), [Eeshit Dhaval Vaishnav](#), [Byron Lee](#), [Tiago R D Costa](#), [José R Penadés](#), [Gary Peltz](#), [Yunhan Xu](#), [Annalisa Pawlosky](#), [Alan Karthikesalingam](#), [Vivek Natarajan](#)

Scientific discovery relies on scientists generating novel hypotheses that undergo rigorous experimental validation. To augment this process, we introduce an AI co-scientist, a multi-agent system built on Gemini 2.0. The AI co-scientist is intended to help uncover new, original knowledge and to formulate demonstrably novel research hypotheses and proposals, building upon prior evidence and aligned to scientist-provided research objectives and guidance. The system's design incorporates a generate, debate, and evolve approach to hypothesis generation, inspired by the scientific method and accelerated by scaling test-time compute. Key contributions include: (1) a multi-agent architecture with an asynchronous task execution framework for flexible compute scaling; (2) a tournament evolution



process for self-improving hypotheses generation. Automated evaluations show continued benefits of test-time compute, improving hypothesis quality. While general purpose, we focus development and validation in three biomedical areas: drug repurposing, novel target discovery, and explaining mechanisms of bacterial evolution and anti-microbial resistance. For drug repurposing, the system proposes candidates with promising validation findings, including candidates for acute myeloid leukemia that show tumor inhibition in vitro at clinically applicable concentrations. For novel target discovery, the AI co-scientist proposed new epigenetic targets for liver fibrosis, validated by anti-fibrotic activity and liver cell regeneration in human hepatic organoids. Finally, the AI co-scientist recapitulated unpublished experimental results via a parallel in silico discovery of a novel gene transfer mechanism in bacterial evolution. These results, detailed in separate, co-timed reports, demonstrate the potential to augment biomedical and scientific discovery and usher an era of AI empowered scientists.

[arXiv:2502.15867](#) [[pdf](#), [other](#)]

### **[Strategic priorities for transformative progress in advancing biology with proteomics and artificial intelligence](#)**

[Yingying Sun](#), [Jun A](#), [Zhiwei Liu](#), [Rui Sun](#), [Liuqia Qian](#), [Samuel H. Payne](#), [Wout Bittremieux](#), [Markus Ralser](#), [Chen Li](#), [Yi Chen](#), [Zhen Dong](#), [Yasset Perez-Riverol](#), [Asif Khan](#), [Chris Sander](#), [Ruedi Aebersold](#), [Juan Antonio Vizcaíno](#), [Jonathan R Krieger](#), [Jianhua Yao](#), [Han Wen](#), [Linfeng Zhang](#), [Yunping Zhu](#), [Yue Xuan](#), [Benjamin Boyang Sun](#), [Liang Qiao](#), [Henning Hermjakob](#), [Haixu Tang](#), [Huanhuan Gao](#), [Yamin Deng](#), [Qing Zhong](#), [Cheng Chang](#), [Nuno Bandeira](#), [Ming Li](#), [Weinan E](#), [Siqi Sun](#), [Yuedong Yang](#), [Gilbert S. Omenn](#), [Yue Zhang](#), [Ping Xu](#), [Yan Fu](#), [Xiaowen Liu](#), [Christopher M. Overall](#), [Yu Wang](#), [Eric W. Deutsch](#), [Luonan Chen](#), [Jürgen Cox](#), [Vadim Demichev](#), [Fuchu He](#), [Jiaxing Huang](#), [Huilin Jin](#), [Chao Liu](#), [Nan Li](#), [Zhongzhi Luan](#), [Jiangning Song](#), [Kaicheng Yu](#), [Wanggen Wan](#), [Tai Wang](#), [Kang Zhang](#), [Le Zhang](#), [Peter A. Bell](#), [Matthias Mann](#), [Bing Zhang](#), [Tiannan Guo](#)

Artificial intelligence (AI) is transforming scientific research, including proteomics. Advances in mass spectrometry (MS)-based proteomics data quality, diversity, and scale, combined with groundbreaking AI techniques, are unlocking new challenges and opportunities in biological discovery. Here, we highlight key areas where AI is driving innovation, from data analysis to new biological insights. These include developing an AI-friendly ecosystem for proteomics data generation, sharing, and analysis; improving peptide and protein identification and quantification; characterizing protein-protein interactions and protein complexes; advancing spatial and perturbation proteomics; integrating multi-omics data; and ultimately enabling AI-empowered virtual cells.

[arXiv:2502.15597](#) [[pdf](#), [html](#), [other](#)]

### **[From FAIR to CURE: Guidelines for Computational Models of Biological Systems](#)**

[Herbert M. Sauro](#), [Eran Aqmon](#), [Michael L. Blinov](#), [John H. Gennari](#), [Joe Hellerstein](#), [Adel Heydarabadipour](#), [Peter Hunter](#), [Bartholomew E. Jardine](#), [Elebeoba May](#), [David P. Nickerson](#), [Lucian P. Smith](#), [Gary D Bader](#), [Frank Bergmann](#), [Patrick M. Boyle](#), [Andreas Drager](#), [James R. Faeder](#), [Song Feng](#), [Juliana Freire](#), [Fabian Frohlich](#), [James A. Glazier](#), [Thomas E. Gorochoowski](#), [Tomas Helikar](#), [Stefan Hoops](#), [Princess Imoukhuede](#), [Sarah M. Keating](#), [Matthias Konig](#), [Reinhard Laubenbacher](#), [Leslie M. Loew](#), [Carlos F. Lopez](#), [William W. Lytton](#), [Andrew McCulloch](#), [Pedro Mendes](#), [Chris J. Myers](#), [Jerry G. Myers](#), [Lealem Mulugeta](#), [Anna Niarakis](#), [David D. van Niekerk](#), [Brett G. Olivier](#), [Alexander A. Patrie](#), [Ellen M. Quardokus](#), [Nicole Radde](#), [Johann M. Rohwer](#), [Sven Sahle](#), [James C. Schaff](#), [T.J. Sego](#), [Janis Shin](#), [Jacky L. Snoep](#), [Rajanikanth Vadigepalli](#), [H. Steve Wiley](#), [Dagmar Waltemath](#), [Ion Moraru](#)

Guidelines for managing scientific data have been established under the FAIR principles requiring that data be Findable, Accessible, Interoperable, and Reusable. In many scientific disciplines, especially computational biology, both data and models are key to progress. For this reason, and recognizing that such models are a very special type of 'data', we argue that computational models, especially mechanistic models prevalent in medicine, physiology and systems biology, deserve a complementary set of guidelines. We propose the CURE principles, emphasizing that models should be Credible, Understandable, Reproducible, and Extensible. We delve into each principle, discussing verification,

validation, and uncertainty quantification for model credibility; the clarity of model descriptions and annotations for understandability; adherence to standards and open science practices for reproducibility; and the use of open standards and modular code for extensibility and reuse. We outline recommended and baseline requirements for each aspect of CURE, aiming to enhance the impact and trustworthiness of computational models, particularly in biomedical applications where credibility is paramount. Our perspective underscores the need for a more disciplined approach to modeling, aligning with emerging trends such as Digital Twins and emphasizing the importance of data and modeling standards for interoperability and reuse. Finally, we emphasize that given the non-trivial effort required to implement the guidelines, the community moves to automate as many of the guidelines as possible.

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 01 Mar 2025]

*Open Letter metrics Revised*

### **Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration**

[version 2; peer review: 1 approved]

E. Wangeci Kagucia, Shirine Voller, Abdhahah K. Ziraba, Godfrey Bigogo, Patrick K. Munywoki, Kimani Makobu, D. James Nokes, James Nyagwange, Cameline Orlando, Donald Akech, Antipa Sigilai, Clayton Onyango, Bonventure Juma, Amy Herman-Roloff, Peninah Munyua, Caroline Apondi, Shirley Lidechi, Allan Audi, Alice Ouma, George Aol, Thomas Misore, Caroline Nasimiyu, Dickens Onyango, Terrence Lo, Kadondi Kasera, Rose Jalang'o, Leonard Kingwara, Ifedayo Adetifa, Anthony O. Etyang, George Warimwe, Ambrose Agweyu, J. Anthony G. Scott

Peer Reviewers Moses Masika

Funders

Bill & Melinda Gates Foundation

US CDC through a Cooperative Agreement to Washington State University Global Health Kenya

Wellcome Trust

LATEST VERSION PUBLISHED 27 Feb 2025

#### *Abstract*

The Kenya Multi Site Serosurveillance (KEMIS) collaboration set out to implement an integrated, nationally representative, population-based program of serological surveillance for past infection for a number of important infectious diseases in Kenya. The project started in December 2021 and built on a portfolio of SARS-CoV-2 research conducted in 2020 and 2021. In this profile paper, we describe the background of the KEMIS collaboration, its aim and objectives, the Health and Demographic Surveillance System sites that were involved in data collection, and the key activities undertaken. We also explain how we established governance and management of the KEMIS collaboration, and reflect on opportunities, challenges, lessons learned, and future directions.

## **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 01 Mar 2025]

[Filter: All articles]

### **Knowledge, Attitudes and Acceptance of COVID-19 Vaccine among Pregnant Women in Mbeya Region**

Revocatus Lawrence Kabanga, Vincent John Chambo, Rebecca Mokeha

medRxiv 2025.02.26.25322935; doi: <https://doi.org/10.1101/2025.02.26.25322935>

### **The effect of bivalent HPV vaccination against invasive cervical cancer and CIN3+ in the Netherlands: a national linkage study**

Marit Middeldorp, Jesca G.M. Brouwer, Janneke W. Duijster, Mirjam J. Knol, Folkert J. van Kemenade, Albert G. Siebers, Johannes Berkhof, Hester E. de Melker  
medRxiv 2025.02.27.25322519; doi: <https://doi.org/10.1101/2025.02.27.25322519>

**Re-examining the meningitis belt: associations between environmental factors and epidemic meningitis risk across Africa**

Molly Cliff, Sally Jahn, Andre Bitá Fouda, Anderson Latt, Clement Lingani, Caroline Trotter  
medRxiv 2025.02.25.25322867; doi: <https://doi.org/10.1101/2025.02.25.25322867>

**Routine immunization intensification, vaccination campaigns, and measles transmission in Southern Nigeria**

Niket Thakkar, Avuwa Joseph Oteri, Kevin McCarthy  
medRxiv 2025.02.24.25322796; doi: <https://doi.org/10.1101/2025.02.24.25322796>

**Increasing dengue outbreaks in temperate Brazil is linked to *Aedes aegypti* invasion and infestation level driving widespread virus transmission**

Thales Bermann, Tatiana Schaffer Gregianini, Fernanda Marques Godinho, Ludmila Fiorenzano Baethgen, Fernanda Letícia Martiny, Erica Bortoli Möllmann, Amanda Pellenz Ruivo, Franciellen Machado dos Santos, Caroline do Nascimento Ferreira, Gustavo Barbosa de Lima, Danielly Alves Mendes Barbosa, Filipe Zimmer Dezordi, Milena Bauermann, Taina Machado Selayaran, Elgion Lucio da Silva Loreto, Felipe Gomes Naveca, André Luiz Sá de Oliveira, Ana Beatriz Gorini da Veiga, Marcelo Henrique Santos Paiva, de Lima Tulio Campos, Gonzalo Bello, Matheus Filgueira Bezerra, Felipe Valter de Oliveira, Rafael Maciel-de-Freitas, Tiago Gräf, Richard Steiner Salvato, Gabriel Luz Wallau  
medRxiv 2025.02.24.25322773; doi: <https://doi.org/10.1101/2025.02.24.25322773>

**Knowledge, Attitude, and Practice among school students and teachers about the Human Papillomavirus vaccine in Central Kerala- a cross-sectional study**

Thomas Pious, Anjum John, V.R Reshma, Mercy John Idicula  
medRxiv 2025.02.24.25322810; doi: <https://doi.org/10.1101/2025.02.24.25322810>

**The implementation of KPI (key performance indicators) to manage the Pharmacovigilance System of a public vaccine producer in Brazil**

Mayra M. M. Oliveira, Fernanda L. C. Oliveira, Vera L. Gattás, Clarissa L. Santos, Gabriela A. Wagner, Monica Taminato  
medRxiv 2025.02.23.25322752; doi: <https://doi.org/10.1101/2025.02.23.25322752>

**Using large language models to understand the public discourse towards vaccination in Brazil between January 2013 and December 2019**

Laura Espinosa, Marcel Salathé  
medRxiv 2025.02.24.25322766; doi: <https://doi.org/10.1101/2025.02.24.25322766>

**First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults**

Laina D. Mercer, Arlene C. Seña, E. Ross Colgate, Jessica W. Crothers, Peter F. Wright, Mohamed Al-Ibrahim, Erman Tritama, Annelet Vincent, Bernardo A. Mainou, Yiting Zhang, Jennifer Konopka-Anstadt, Ananda S. Bandyopadhyay, Alan Fix, John O. Konz, Chris Gast  
medRxiv 2025.02.21.25322566; doi: <https://doi.org/10.1101/2025.02.21.25322566>

**Impact assessment of vaccine-related negative news and incentive measures on vaccine hesitancy in Hong Kong**

Yifan Chen, Yang Ye, Hsiang-Yu Yuan, Qingpeng Zhang

## OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

## Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 01 Mar 2025]

Research Note Open Access

**REVISED - Recruitment strategies used to enrol healthy volunteers in the first pneumococcal human infection study in Africa: Lessons from Blantyre, Malawi**

[version 2; peer review: 2 approved with reservations]

Edna Nsomba \* et al. for the Malawi Accelerated Research in Vaccines, Experimental Laboratory Systems (MARVELS) consortium

Abstract

Background

Human Infection Studies (HIS) also known as Controlled Human Infection Models (CHIM) are a relatively new concept in African countries to clinicians, scientists, and communities alike. We have introduced HIS/CHIM studies to Malawi during the last four years by developing an experimental human pneumococcal carriage model. This CHIM was used to test the efficacy of a licensed 13-valent Pneumococcal Conjugate Vaccine (PCV13) against experimental nasal pneumococcal carriage. Traditional and digital recruitment strategies into this novel trial were explored.

\* \* \* \*

## **Think Tanks**

**Brookings** [to 01 Mar 2025]

<http://www.brookings.edu/>

Reports, Events

No new digest content identified.

**Center for Global Development** [to 01 Mar 2025]

<https://www.cgdev.org/>

All Research

No new digest content identified.

**Chatham House** [to 01 Mar 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

**Council on Foreign Relations** [to 01 Mar 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*  
*No new digest content identified.*

**CSIS** [to 01 Mar 2025]  
<https://www.csis.org/>  
*Reports [Selected]*  
*No new digest content identified.*

**Kaiser Family Foundation** [to 01 Mar 2025]  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*  
*Latest Research*  
*No new digest content identified.*

**McKinsey Global Institute** [to 01 Mar 2025]  
<https://www.mckinsey.com/mgi/overview>  
*Latest Research*  
*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 01 Mar 2025]  
<https://odi.org/en/publications/>  
*Publications [Selected]*  
*No new digest content identified.*

**Pew Research Center** [to 01 Mar 2025]  
<https://www.pewresearch.org/>  
*Latest Publications [Selected]*  
*feature Feb 26, 2025*

**[Religious Landscape Study: Database](#)**

The Religious Landscape Study is a comprehensive survey of more than 35,000 Americans' religious identities, beliefs and practices that's been conducted in 2007, 2014 and 2023-24. Pew Research Center.

**Rand** [to 01 Mar 2025]  
<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*Working Papers Feb 28, 2025*

**[Automated Grading for Efficiently Evaluating the Dual-Use Biological Capabilities of Large Language Models](#)**

The authors used an automated grader to evaluate the ability of large language models to answer knowledge-based questions and generate stepwise instructions for common laboratory techniques that could be used to create biological threat proxies.

**Urban Institute** [to 01 Mar 2025]  
<https://www.urban.org/publications>

**New Research Publications - Selected**

*Research Report*

**Reducing Federal Support for Medicaid Expansion Would Shift Costs to States and Likely Result in Coverage Losses**

February 24, 2025

**World Economic Forum** [to 01 Mar 2025]

<https://agenda.weforum.org/press/>

*Media [Selected]*

**World Economic Forum to Launch European Centre for AI Excellence in Paris**

Published 27 Feb 2025

- The World Economic Forum is partnering with VivaTech to establish a European Centre for AI Excellence (CAIE) in Paris to strengthen Europe’s position as a global leader in AI.
- The centre will leverage France’s strong research ecosystem, robust technology investment landscape and dynamic start-up scene to drive innovation and adoption.
- Building on the momentum of the [AI Action Summit](#), the centre will join the Forum’s Fourth Industrial Revolution (C4IR) Network as the first centre in Europe focused on AI innovation.
- Learn more about the global C4IR Network [here](#) and read the 2023-2024 C4IR Network Impact Report [here](#).

\* \* \* \*

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*